A study in the August 2007 issue of Pediatric Diabetes supports the use of the GlycoMark (Kannapolis, North Carolina) 1,5-anhydroglucitol (1,5-AG) blood test to evaluate therapy in children with diabetes, especially to target postprandial hyperglycemia (elevated after-meal glucose levels). Controlling after-meal glucose levels is important in achieving optimal glycemic control and reducing the burden of cardiovascular complications, the leading cause of death in patients. GlycoMark is an FDA approved test for monitoring intermediate glycemic control by measuring the levels of a monosaccharide 1,5-anhydroglucitol (1,5-AG) in blood. Multiple published studies in peer-reviewed journals have shown that the 1,5-AG test is a specific index of postprandial hyperglycemia (elevated after-meal glucose levels) and short-term glycemic control — providing a useful complement to A1C testing.

The Molecular Profiling Institute (Phoenix) said that they are now providing Mammostrat, a new molecular-targeted breast prognostic test, to breast cancer patients. The Mammostrat prognostic test uses five immunohistochemical biomarkers to classify patients into high-, moderate-, or low-risk categories for disease recurrence. Mammostrat uses traditional immunohistochemistry technology, and the test is expected to be less expensive than existing molecular-based, prognostic tests for breast cancer and is typically covered by insurance. The Molecular Profiling Institute is a CLIA-certified specialty reference laboratory that helps patients by applying the discoveries of the Human Genome Project to personalized medicine.

• Power3 Medical Products (Houston), has concluded the initial phase of its international validation study of its blood serum biomarker test for Parkinson’s diseases. The samples used in the study showed that the changes in the blood serum concentration of the protein biomarkers were consistent with previous Power3 results obtained in the U.S. from Parkinson’s disease patients. Power3 has validated its method for collection, storage, shipping, processing, and biostatistical analysis protocols. In validating the company’s method of testing, the study confirms Power3’s ability to reproduce its Parkinson’s disease diagnostic test results with superior sensitivity and specificity. Power3 is a proteomics company specializing in diagnostic tests for early detection of breast cancer and neurodegenerative diseases.

• Siemens Medical Solutions (Malvern, Pennsylvania) said that it has added the ImageGrid archive appliance from Candelis (Irvine, California) to its accessory solutions product portfolio. The fully integrated multimodality storage drive is offered through Siemens’ global sales and distribution channels. The ImageGrid is fully compliant with DICOM (Digital Imaging and Communications in Medicine) standards. It provides healthcare facilities a scalable storage solution to accommodate the increasingly larger volumes of data and images generated by medical imaging modalities, such as mammography, computed tomography, molecular imaging and ultrasound. Candelis is a medical informatics company; Siemens Medical Solutions provides medical technologies, healthcare information systems, management consulting, and support services.

• Whatman (Florham Park, New Jersey) said that it will provide DNA collection kits based on its FTA elute technology for a pharmacogenotyping study looking at genetic markers in prostate cancer. The international study is part of the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial. STAMPEDE is a multi-stage, randomized, controlled trial for patients with newly diagnosed advanced prostate cancer or for patients with a rapid PSA rise following previous surgery or radiotherapy. The sub study is designed to increase understanding of metabolic pathways by which androgen blocking drugs affect patients. Each patient with advanced prostate cancer, who will participate in one of the five stages of the study, will have the option to contribute a sample of genetic material using the Whatman FTA Elute kit. FTA Elute utilizes a chemically-treated matrix that lyses cells and immobilizes nucleic acids on contact, enabling scientists to collect, transport, archive, and isolate DNA and RNA samples at room temperature in a single step. Whatman specializes in separations technology.

No Comments